U.S.: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in the U.S.

The U.S. prophylactic medicaments containing insulin market stood at $X in 2022, with an increase of 8.2% against the previous year. Overall, consumption continues to indicate a strong increase. Prophylactic medicaments containing insulin consumption peaked at $X in 2020; however, from 2021 to 2022, consumption failed to regain momentum.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in the U.S.

In value terms, prophylactic medicaments containing insulin production expanded rapidly to $X in 2022. Overall, production continues to indicate resilient growth. The pace of growth appeared the most rapid in 2020 with an increase of 49%. As a result, production attained the peak level of $X. From 2021 to 2022, production growth remained at a lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports from the U.S.

In 2022, overseas shipments of medicaments containing insulin but not antibiotics in measured doses increased by 59% to X tons for the first time since 2019, thus ending a two-year declining trend. Overall, total exports indicated a noticeable expansion from 2012 to 2022: its volume increased at an average annual rate of +4.3% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. As a result, the exports reached the peak and are likely to continue growth in the immediate term.

In value terms, prophylactic medicaments containing insulin exports surged to $X in 2022. Over the period under review, exports continue to indicate a resilient expansion. As a result, the exports attained the peak and are likely to continue growth in the immediate term.

Exports by Country

Denmark (X tons) was the main destination for prophylactic medicaments containing insulin exports from the United States, with a 35% share of total exports. Moreover, prophylactic medicaments containing insulin exports to Denmark exceeded the volume sent to the second major destination, Japan (X tons), twofold. Mexico (X tons) ranked third in terms of total exports with a 15% share.

From 2012 to 2022, the average annual rate of growth in terms of volume to Denmark totaled +61.2%. Exports to the other major destinations recorded the following average annual rates of exports growth: Japan (+1.6% per year) and Mexico (+7.8% per year).

In value terms, Canada ($X), Mexico ($X) and Denmark ($X) constituted the largest markets for prophylactic medicaments containing insulin exported from the United States worldwide, with a combined 67% share of total exports. Brazil, Japan, Spain, Pakistan and Germany lagged somewhat behind, together comprising a further 22%.

In terms of the main countries of destination, Spain, with a CAGR of +120.0%, recorded the highest rates of growth with regard to the value of exports, over the period under review, while shipments for the other leaders experienced more modest paces of growth.

Export Prices by Country

In 2022, the average prophylactic medicaments containing insulin export price amounted to $X per ton, falling by -3.7% against the previous year. In general, export price indicated a perceptible expansion from 2012 to 2022: its price increased at an average annual rate of +2.1% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, prophylactic medicaments containing insulin export price increased by +72.4% against 2018 indices. The most prominent rate of growth was recorded in 2020 an increase of 53%. The export price peaked at $X per ton in 2021, and then shrank modestly in the following year.

Prices varied noticeably by country of destination: amid the top suppliers, the country with the highest price was Canada ($X per ton), while the average price for exports to Denmark ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to Canada (+47.1%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports into the U.S.

In 2022, overseas purchases of medicaments containing insulin but not antibiotics in measured doses increased by 1.8% to X tons, rising for the third year in a row after three years of decline. The total import volume increased at an average annual rate of +1.4% from 2012 to 2022; however, the trend pattern indicated some noticeable fluctuations being recorded throughout the analyzed period. The pace of growth appeared the most rapid in 2016 when imports increased by 28%. As a result, imports attained the peak of X tons. From 2017 to 2022, the growth of imports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin imports reduced to $X in 2022. Over the period under review, imports, however, saw a deep downturn. The most prominent rate of growth was recorded in 2014 with an increase of 37%. As a result, imports reached the peak of $X. From 2015 to 2022, the growth of imports failed to regain momentum.

Imports by Country

In 2022, Germany (X tons) constituted the largest prophylactic medicaments containing insulin supplier to the United States, accounting for a 73% share of total imports. Moreover, prophylactic medicaments containing insulin imports from Germany exceeded the figures recorded by the second-largest supplier, Malaysia (X tons), fivefold. The third position in this ranking was held by France (X tons), with a 7.5% share.

From 2012 to 2022, the average annual rate of growth in terms of volume from Germany was relatively modest. The remaining supplying countries recorded the following average annual rates of imports growth: Malaysia (+399.4% per year) and France (+23.9% per year).

In value terms, Germany ($X) constituted the largest supplier of medicaments containing insulin but not antibiotics in measured doses to the United States, comprising 74% of total imports. The second position in the ranking was taken by France ($X), with a 10% share of total imports. It was followed by Denmark, with a 6.3% share.

From 2012 to 2022, the average annual growth rate of value from Germany stood at -10.3%. The remaining supplying countries recorded the following average annual rates of imports growth: France (+17.1% per year) and Denmark (-11.7% per year).

Import Prices by Country

In 2022, the average prophylactic medicaments containing insulin import price amounted to $X per ton, falling by -12.7% against the previous year. Over the period under review, the import price recorded a deep slump. The growth pace was the most rapid in 2014 an increase of 17% against the previous year. As a result, import price reached the peak level of $X per ton. From 2015 to 2022, the average import prices remained at a somewhat lower figure.

There were significant differences in the average prices amongst the major supplying countries. In 2022, amid the top importers, the country with the highest price was Denmark ($X per ton), while the price for Malaysia ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Malaysia (+12.4%), while the prices for the other major suppliers experienced a decline.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :